1
|
Yao LW, Wu LL, Zhang LH, Zhou W, Wu L, He K, Ren JC, Deng YC, Yang DM, Wang J, Mu GG, Xu M, Zhou J, Xiang GA, Ding QS, Yang YN, Yu HG. MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway. Oncogenesis 2020; 9:17. [PMID: 32054827 PMCID: PMC7018958 DOI: 10.1038/s41389-020-0198-z] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 12/23/2019] [Accepted: 01/23/2020] [Indexed: 12/17/2022] Open
Abstract
Gastric cancer (GC) is one of the most common malignancies and its prognosis is extremely poor. This study identifies a novel oncogene, microfibrillar-associated protein 2 (MFAP2) in GC. With integrative reanalysis of transcriptomic data, we found MFAP2 as a GC prognosis-related gene. And the aberrant expression of MFAP2 was explored in GC samples. Subsequent experiments indicated that silencing and exogenous MFAP2 could affect motility of cancer cells. The inhibition of silencing MFAP2 could be rescued by another FAK activator, fibronectin. This process is probably through affecting the activation of focal adhesion process via modulating ITGB1 and ITGA5. MFAP2 regulated integrin expression through ERK1/2 activation. Silencing MFAP2 by shRNA inhibited tumorigenicity and metastasis in nude mice. We also revealed that MFAP2 is a novel target of microRNA-29, and miR-29/MFAP2/integrin α5β1/FAK/ERK1/2 could be an important oncogenic pathway in GC progression. In conclusion, our data identified MFAP2 as a novel oncogene in GC and revealed that miR-29/MFAP2/integrin α5β1/FAK/ERK1/2 could be an important oncogenic pathway in GC progression.
Collapse
Affiliation(s)
- Li-Wen Yao
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Lian-Lian Wu
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Li-Hui Zhang
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Wei Zhou
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Lu Wu
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Ke He
- Department of General Surgery, The Second People's Hospital of Guangdong Province, Southern Medical University, Guangzhou, Guangdong, 510317, P.R. China.,Department of Biochemistry, Zhongshan Medical College, Sun Yat-sen University, Guangzhou, P.R. China
| | - Jia-Cai Ren
- Department of Pathology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Yun-Chao Deng
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Dong-Mei Yang
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Jing Wang
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Gang-Gang Mu
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Ming Xu
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Jie Zhou
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China
| | - Guo-An Xiang
- Department of General Surgery, The Second People's Hospital of Guangdong Province, Southern Medical University, Guangzhou, Guangdong, 510317, P.R. China
| | - Qian-Shan Ding
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China. .,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.
| | - Yan-Ning Yang
- Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.
| | - Hong-Gang Yu
- Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China. .,Hubei Key laboratory of Digestive System, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, P.R. China.
| |
Collapse
|
2
|
Juritz EI, Bascur JP, Almonacid DE, González-Nilo FD. Novel Insights for Inhibiting Mutant Heterodimer IDH1 wt-R132H in Cancer: An In-Silico Approach. Mol Diagn Ther 2018; 22:369-380. [PMID: 29651790 DOI: 10.1007/s40291-018-0331-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
BACKGROUND Isocitrate dehydrogenase 1 (IDH1) is a dimeric enzyme responsible for supplying the cell's nicotinamide adenine dinucleotide phosphate (NADPH) reserves via dehydrogenation of isocitrate (ICT) and reduction of NADP+. Mutations in position R132 trigger cancer by enabling IDH1 to produce D-2-hydroxyglutarate (2-HG) and reduce inhibition by ICT. Mutant IDH1 can be found as a homodimer or a heterodimer. OBJECTIVE We propose a novel strategy to inhibit IDH1 R132 variants as a means not to decrease the concentration of 2-HG but to provoke a cytotoxic effect, as the cell malignancy at this point no longer depends on 2-HG. We aim to inhibit the activity of the mutant heterodimer to block the wild-type subunit. Limiting the NADPH reserves in a cancerous cell will enhance its susceptibility to the oxidative stress provoked by chemotherapy. METHODS We performed a virtual screening using all US FDA-approved drugs to replicate the loss of inhibition of mutant IDH1 by ICT. We characterized our results based on molecular interactions and correlated them with the described phenotypes. RESULTS We replicated the loss of inhibition by ICT in mutant IDH1. We identified 20 drugs with the potential to inhibit the heterodimeric isoform. Six of them are used in cancer treatment. CONCLUSIONS We present 20 FDA-approved drugs with the potential to inhibit IDH1 wild-type activity in mutated cells. We believe this work may provide important insights into current and new approaches to dealing with IDH1 mutations. In addition, it may be used as a basis for additional studies centered on drugs presenting differential sensitivities to different IDH1 isoforms.
Collapse
Affiliation(s)
- Ezequiel Iván Juritz
- Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la Vida, Universidad Andrés Bello, 8370146, Santiago, Chile.
| | - Juan Pablo Bascur
- Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la Vida, Universidad Andrés Bello, 8370146, Santiago, Chile
| | - Daniel Eduardo Almonacid
- Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la Vida, Universidad Andrés Bello, 8370146, Santiago, Chile.,uBiome, Inc., San Francisco, CA, USA
| | - Fernando Danilo González-Nilo
- Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la Vida, Universidad Andrés Bello, 8370146, Santiago, Chile.,Centro Interdisciplinario de Neurociencia de Valparaíso, Facultad de Ciencias, Universidad de Valparaíso, 2366103, Valparaíso, Chile
| |
Collapse
|